Production of Adenovector Based Vaccines

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,470,960.00
Award Year:
2009
Program:
SBIR
Phase:
Phase II
Contract:
2R44AI063819-03A1
Agency Tracking Number:
AI063819
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
GENVEC, INC.
GENVEC, INC., 65 W WATKINS MILL RD, GAITHERSBURG, MD, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
806729547
Principal Investigator:
DUNCAN MCVEY
(240) 632-5546
Business Contact:
WEST
() -
dbrough@genvec.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Adenovirus vectors (Advectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numerous Advectors expressing a variety of antigens a substant ial subset of antigen genes have been found to be inhibitory to Advector construction and production. This limitation was resolved in our phase I research by blocking antigen expression with a repressor system that is over 50-fold stronger than the commonl y used TetR system. The technology was demonstrated to be applicable to multiple serotype groups of Advectors. In this phase 2 SBIR grant application we propose to use our optimized repressor to make a production cell line that is broadly applicable to vac cine vectors based on different human serotype groups and encoding inhibitory antigens. At the end of this phase 2 research a cell line certified ready for use in GMP banking will be available. No such cell line presently exists. The strategy to make the p referred repressor cell line is described in the three aims of this proposal. In Aim 1 the preferred repressor cell line with an optimized expression cassette will be constructed. Development of an optimized expression cassette is required to circumvent th e epigenetic silencing found with the expression cassette used in our phase 1 research. In Aim 2 the preferred repressor cell line will be identified and certified for use in GMP banking. Since it is anticipated that Advector vaccines will be produced in s uspension cells for commercial purposes, in Aim 3 we will demonstrate that the preferred repressor cell line can be adapted to grow in suspension and support production of Advectors from multiple serotype groups with inhibitory antigens. The final GMP manu facturing cell line will speed and facilitate the testing of Advector vaccine concepts for many antigens, hasten their progress to clinical testing and reduce the cost of goods for future approved vaccine products. PUBLIC HEALTH RELEVANCE: Adenovirus vecto r-based vaccines show great promise for protecting against many human diseases. However, some promising vaccines can not be made. In this proposal we overcome this limitation by developing a cell line that ensures any Adenovirus vector vaccine can be produ ced.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government